AVTX NASDAQ
Avalo Therapeutics, Inc.
1W: -45.4%
1M: -55.2%
3M: -64.5%
YTD: -60.3%
1Y: -61.6%
3Y: -77.1%
5Y: -99.9%
$6.75
-0.02 (-0.30%)
Pre-Market: $6.73 (-0.02, -0.30%)
Weekly Expected Move ±20.7%
$4
$5
$7
$8
$10
Credit Risk of going bust: lower than 74% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Avalo Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242K against a stock market value of $362.0M.
Distance to default 8.27 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $121K (short-term plus half of long-term), stock volatility 92.2%; Altman Z'' 11.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Avalo Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242K against a stock market value of $362.0M.
Distance to default 8.27 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $121K (short-term plus half of long-term), stock volatility 92.2%; Altman Z'' 11.63. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (46)
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Stock Has Average Target Price of $45.10 According to Brokerages
Avalo Therapeutics (NASDAQ:AVTX) Hits New 52-Week Low – Time to Sell?
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Down 5.8% – Here’s What Happened
Christopher Ryan Sullivan Sells 12,394 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock
Bank of New York Mellon Corp Makes New Investment in Avalo Therapeutics, Inc. $AVTX
Catalyst Watch: Tech majors report, FOMC, Jersey Mike's IPO and more oil anxiety
Avalo Therapeutics to join Russell 2000, 3000 indexes
Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
This Sailpoint Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday
This Keurig Dr Pepper Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Avalo Therapeutics Stock Jumps 33% In Pre-Market Session: Here's Why
Avalo Therapeutics prices $375M public offering; shares jump
Avalo Therapeutics launches public stock and warrant offering
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
Avalo Therapeutics Purchases Optional Milestone Buyout
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $42.25
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $10,864.00 in Stock
Christopher Ryan Sullivan Sells 7,979 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock
Christopher Ryan Sullivan Sells 7,980 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
HC Wainwright Has Positive Outlook for AVTX Q1 Earnings
CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer
Earnings Scheduled For March 23, 2026
Avalo Therapeutics GAAP EPS of -$5.84 beats by $0.47, revenue of $0.06M
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
12 Health Care Stocks Moving In Thursday's After-Market Session
Avalo Therapeutics, Inc. $AVTX Shares Acquired by Boothbay Fund Management LLC
Cantor Fitzgerald L. P. Acquires New Position in Avalo Therapeutics, Inc. $AVTX
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $33.00
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $34.88
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $32.71 Consensus Price Target from Analysts
Reviewing Avalo Therapeutics (NASDAQ:AVTX) and Aditxt (NASDAQ:ADTX)